Headshot photo of Paul Yang, M.D., Ph.D.

Accepting new patients

Paul Yang, M.D., Ph.D.

Accepting new patients

  • Chief, Paul H. Casey Ophthalmic Genetics Division
  • Associate Professor of Ophthalmology, School of Medicine


  • Ophthalmology

Special focus

  • Retinal Dystrophies Congenital/Genetic Disease

Locations and contact

I see patients at

About me

Dr. Paul Yang was born in Taiwan and raised in Bellevue, Washington. He received his undergraduate degrees in bioengineering and biochemistry at the University of Washington in Seattle, during which he was awarded multiple summer research grants from the Howard Hughes Medical Institute, as well as the Mary Gates Endowment for Students. He received doctorates in medicine and neurophysiology at Dartmouth Medical School, which was funded by an individual M.D./Ph.D. pre-doctoral national research service award from the National Institutes of Health. He completed an internship in internal medicine at the University of Utah, and residency and fellowship in ophthalmology at the Moran Eye Center in Salt Lake City.

It was during his time at the Moran Eye Center where he first developed an interest in inflammatory eye diseases and degenerative retinal disorders under the guidance of Drs. Albert Vitale, Paul Bernstein, and Donnell Creel. Thereafter, he pursued a fellowship in ocular immunology and uveitis with Dr. Stephen Foster at the Massachusetts Eye Research and Surgery Institution in Cambridge, Massachusetts, as well as a fellowship in ophthalmic genetics and inherited retinal degenerations with Richard Weleber, M.D., and Mark Pennesi, M.D., Ph.D., at Casey Eye Institute in Portland, Oregon.

During his training at Casey Eye Institute, Dr. Yang was funded by The Foundation Fighting Blindness under the Alan Laties Career Development Program, where he conducted laboratory studies to evaluate the effectiveness of immunomodulatory therapy in reducing secondary collateral damage in retinitis pigmentosa.

Dr. Yang is chief of the Paul H. Casey Ophthalmic Genetics Division and Martha and Eddie Peterson Endowed Professor at OHSU Casey Eye Institute. He also has special interest in gene therapy associated uveitis (GTU), autoimmune retinopathy, and cataract surgery in patients with inherited retinal degenerations. The focus of his research is to better understand the mechanisms of immune-mediated damage in inherited retinal degenerations and autoimmune retinopathy. With the support of the Foundation Fighting Blindness, he is currently conducting translational research in an effort to bring new medical treatments to the clinic for patients with retinitis pigmentosa. Dr. Yang is also principal investigator on multiple industry-sponsored retinal gene therapy clinical trials for inherited retinal degenerations.

Languages spoken

  • English
  • Taiwanese

Education and training

    • B.S.E., 1998, University of Washington
    • B.S., 1998, University of Washington
    • Ph.D., 2004, Dartmouth
    • M.D., 2006, Dartmouth Medical School
  • Residency

    • Ophthalmology residency – John Moran Eye Center, Salt Lake City, UT, 2010
  • Fellowship

    • Ophthalmic genetics and visual electrophysiology – Casey Eye Institute, Portland, OR, 2013
  • Certifications

    • American Board of Ophthalmology, 2013
Read faculty profile


Before scheduling your appointment, we recommend you contact your insurance company to verify that the OHSU Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any copayments, co–insurance, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with OHSU providers, your out of pocket liability may be higher. Visit the billing and insurance section of our site for more information.

Ratings and reviews

Overall: 4.8 out of 5 (63 Ratings, 25 Reviews)

The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys.

  1. {{ item.comments[0]['comment'] }}